Struggling GSK inks a translational deal with QB3

San Francisco incubator QB3 is linking up with pharma giant GlaxoSmithKline ($GSK) on some translational work, looking to push a few academic research projects toward the clinic. [email protected] will work with the folks at GSK to find some promising collaborations to work on. This is the latest in a long lineup of discovery deals for GlaxoSmithKline, which set up its Discovery Partnerships with Academia (DPAc) team to find promising new programs. GSK may be busy in the early-stage field, but it's been losing the interest of Wall Street analysts who are distinctly not excited by its weak set of late-stage prospects. Release

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.